Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History IDYA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics IDYA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Ideaya Biosciences Inc

IDYA
Current price
22.09 USD -0.11 USD (-0.50%)
Last closed 21.43 USD
ISIN US45166A1025
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 939 941 248 USD
Yield for 12 month -46.27 %
1Y
3Y
5Y
10Y
15Y
IDYA
21.11.2021 - 28.11.2021

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Address: 5000 Shoreline Court, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

51.08 USD

P/E Ratio

Dividend Yield

Financials IDYA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures IDYA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+7 000 000 USD

Last Year

+23 385 000 USD

Current Quarter

Last Quarter

+7 000 000 USD

Current Year

+3 166 000 USD

Last Year

+19 377 000 USD

Current Quarter

Last Quarter

+6 357 000 USD
EBITDA -357 976 000 USD
Operating Margin TTM -5 147.81 %
Price to Earnings
Return On Assets TTM -21.84 %
PEG Ratio
Return On Equity TTM -31.34 %
Wall Street Target Price 51.08 USD
Revenue TTM 7 000 000 USD
Book Value 11.70 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 78.50 %
Dividend Yield
Gross Profit TTM -315 753 984 USD
Earnings per share -3.65 USD
Diluted Eps TTM -3.65 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation IDYA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 4.65
Enterprise Value Revenue 187.29
Price Sales TTM 277.13
Enterprise Value EBITDA -7.80
Price Book MRQ 1.93

Technical Indicators IDYA

For 52 Weeks

13.45 USD 44.42 USD
50 Day MA 20.61 USD
Shares Short Prior Month 11 344 383
200 Day MA 23.07 USD
Short Ratio 8.69
Shares Short 11 584 970
Short Percent 15.29 %